Quality of life in fit elderly patients with chronic lymphocytic leukemia (CLL) receiving oral fludarabine-based regimens as first line therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial.

被引:0
|
作者
Sandhu, Suneet [1 ,2 ]
Gill, Devinder [1 ,2 ]
Turner, Paul [1 ,2 ]
Renwick, William [1 ,2 ]
Latimer, Maya [1 ,2 ]
Mackinlay, Naomi [1 ,2 ]
Berkahn, Leanne [1 ,2 ]
Simpson, David [1 ,2 ]
Campbell, Phillip [1 ,2 ]
Forsyth, Cecily [1 ,2 ]
Cull, Gavin [1 ,2 ]
Harrup, Rosemary [1 ,2 ]
Sulda, Melanie [1 ,2 ]
Best, Giles [1 ,2 ]
Bressel, Mathias [1 ,2 ]
Di Iulio, Juliana [1 ,2 ]
Kuss, Bryone [1 ,2 ]
Mulligan, Stephen [1 ,2 ]
机构
[1] Australasian Leukaemia & Lymphoma Grp, Richmond, Vic, Australia
[2] Chron Lymphocyt Leukemia Australian Res Consortiu, Richmond, Vic, Australia
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
34
引用
收藏
页码:27 / 29
页数:3
相关论文
共 32 条
  • [31] A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRM Cancer Research Group (E1912)
    Shanafelt, Tait D.
    Wang, Victoria
    Kay, Neil E.
    Hanson, Curtis A.
    O'Brien, Susan M.
    Barrientos, Jacqueline C.
    Erba, Harry P.
    Stone, Richard M.
    Litzow, Mark R.
    Tallman, Martin S.
    BLOOD, 2018, 132
  • [32] Clinical Outcomes and Adverse Events Among Patients with Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Initiating First-Line (1L) Ibrutinib: Analysis of Subgroups Receiving Subsequent Second Generation (2G) Bruton Tyrosine Kinase Inhibitors, Non-Bruton Tyrosine Kinase Inhibitor Therapy, or Ibrutinib Retreatment in the US Community Oncology Setting
    Burke, John M.
    Zackon, Ira
    Wayne, Brittani
    Wang, Yunfei
    Murphy, John
    Prescott, Jennifer
    Gandra, Shravanthi
    Leng, Siyang
    De Nigris, Enrico
    BLOOD, 2024, 144 : 7811 - 7812